VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized...

Area of Science:

• Microbiology
• Gastroenterology
• Clinical Trials

Background:

• Clostridioides difficile infection (CDI) poses a significant risk for recurrence, particularly in high-risk adult populations.
• The role of commensal Clostridia in preventing CDI recurrence remains largely unknown.
• VE303 is a rationally defined bacterial consortium comprising 8 nonpathogenic, nontoxigenic Clostridia strains.

Purpose of the Study:

• To evaluate the efficacy of VE303 in preventing recurrent CDI in high-risk adults.
• To determine the optimal VE303 dosage for a future phase 3 clinical trial.

Main Methods:

• A Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study was conducted.
• 79 participants with confirmed CDI and high recurrence risk were randomized to high-dose VE303, low-dose VE303, or placebo for 14 days.
• The primary endpoint was CDI recurrence at 8 weeks, assessed using combined clinical and laboratory criteria.

Main Results:

• High-dose VE303 demonstrated a statistically significant reduction in CDI recurrence at 8 weeks compared to placebo (13.8% vs 45.5%, P=.006).
• Low-dose VE303 also showed a trend towards reduced recurrence but did not reach statistical significance compared to placebo (37.0%).
• Baseline characteristics were similar across all treatment groups.

Conclusions:

• High-dose VE303 is effective in preventing recurrent CDI in high-risk adults.
• The findings support further investigation of VE303 in a larger phase 3 study.
• VE303 represents a potential novel therapeutic strategy for CDI prevention.